KRAS and neoplasm: We propose that KRASG12C relies more on KRAS signaling through the MAPK arm to increase oncogenic potential and promote tumor growth rendering advanced KRASG12C tumors more susceptible to MAPK inhibition compared to KRASG12D tumors.